ArticleEClinicalMedicine2026
Predictors of early cancer burden in
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hereditary diffuse gastric cancer (HDGC) with Methods: This is a single centre longitudinal cohort study of CDH1 germline variant carriers recruited at Cambridge University Hospitals (United Kingdom) between 2005 and 2024. We analysed two cohorts: 53 patients who underwent endoscopic evaluation followed by PTG and 93 individuals who received longitudinal surveillance. We excluded patients with advanced cancer at baseline endoscopy. Participants received high-resolution endoscopy with targeted and systematic random biopsies following Cambridge protocol. Multivariable negative binomial regression, logistic regression, and linear mixed-effects models were applied to assess predictors of SRCC burden and temporal dynamics of SRCC detection. Findings: In PTG cohort, 89% individuals had early-stage cancer (pT1aN0M0) and 11% had no evidence of carcinoma (pT0N0M0). The number of SRCC foci ranged from 0 to 273 (median 14, IQR 2-37). The number of positive targeted and random biopsies independently predicted SRCC burden on gastrectomy ( Interpretation: Endoscopic surveillance using systematic biopsies reliably estimates SRCC burden on gastrectomy in HDGC. Individuals with few SRCC lesions showed stable findings during long-term surveillance, supporting the safety of endoscopic monitoring and extended surveillance intervals. Future research should clarify the clinical significance of high SRCC burden. Funding: Medical Research Council and Cancer Research UK.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.